1 / 6

LAMEA Oncology/Anti-Cancer Drugs Market Growth, opportunities and analysis.

LAMEA Oncology/Anti-Cancer Drugs Market report, published by Allied Market Research, forecasts that the market is expected to garner $17,072.2 million by 2021, registering a CAGR of 8.6% during the period 2015 - 2021. Chemotherapy segment is expected to maintain a dominant share in the LAMEA oncology/cancer drugs market during the forecast period.<br><br>Read more :http://bit.ly/2ydd0Kw

shawn966
Download Presentation

LAMEA Oncology/Anti-Cancer Drugs Market Growth, opportunities and analysis.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. LAMEA Oncology/Anti-Cancer Drugs Market Opportunity Analysis and Industry Forecast, 2014 - 2021

  2. LAMEA Oncology/Anti-Cancer Drugs Marketreport, published by Allied Market Research, forecasts that the market is expected to garner $17,072.2 million by 2021, registering a CAGR of 8.6% during the period 2015 - 2021. Chemotherapy segment is expected to maintain a dominant share in the LAMEA oncology/cancer drugs market during the forecast period.

  3. High prevalence and rising incidence rates of major types of cancers (such as breast cancer and prostate cancer), emerging treatment algorithms and widespread use of anti-cancer drugs for treating conditions such as blood cancer (leukemia) is expected to drive this market. In addition, growing popularity of biological and targeted drug therapies, which help in improving the patientssurvival time, are projected to provide opportunities in the LAMEA oncology/anti-cancer drugs market. However, factors such as high cost associated with cancer drugs and related side effects are likely to affect the market growth. • Saudi Arabia, is the leading country market from the Middle East region and would continue to lead until 2020, owing to rising incidence rates of cancer, high healthcare expenditure and gross national income (GNI) in Saudi Arabia. Algeria, is expected to witness highest growth rate because of considerable funding, urbanized healthcare facilities and establishment of national healthcare systems.

  4. Key findings of LAMEA Oncology/Anti-Cancer Drugs Market: • Immunotherapy (biologic therapy) is projected to be the fastest growing segment, registering a CAGR of 12.2% during the forecast period. • Chemotherapy is expected to dominate the LAMEA oncology/cancer drugs market throughout the forecast period. • Blood cancer segment would lead the LAMEA oncology/cancer drugs market through 2021. • Algeria is anticipated to be the fastest growing country in the LAMEA oncology/anti-cancer drugs market, registering a CAGR of 12.8% between 2015 and 2021. • Brazil was the highest revenue generating country in the LAMEA oncology/anti-cancer drugs market with about one third of market share in 2015.

  5. Key players in the market: • Amgen Inc. • AstraZeneca Plc. • Roche Diagnostics • GlaxoSmithKline PLC • Merck & Co. • Novartis AG • AbbVie Inc. Sanofi • EIMC United Pharmaceuticals (EUP) • Actavis plc.

  6. LAMEA Oncology/Anti-cancer drugs Market by Therapeutic Modalities (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy) and Cancer Types (Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Respiratory/Lung Cancer, Skin Cancer) - Opportunity Analysis and Industry Forecast, 2014 – 2021

More Related